



March 11, 2024

**RE: Toviaz<sup>®</sup>, Cerdelga<sup>®</sup>, Zavesca<sup>®</sup>, Alphagan<sup>®</sup> P, Zioptan<sup>®</sup>, Ciprodex<sup>®</sup>, and Floxin<sup>®</sup> Otic Coverage Changes Effective March 25, 2024**

The following changes will take effect March 25, 2024. Complete prior authorization (PA) criteria can be found on the OHCA website at [www.oklahoma.gov/ohca/pa](http://www.oklahoma.gov/ohca/pa). Pharmacy PA forms can be found on the OHCA website at <https://oklahoma.gov/ohca/rxforms>.

**Toviaz<sup>®</sup>**

Toviaz<sup>®</sup> (fesoterodine) will be brand preferred. Members currently utilizing generic fesoterodine will need to switch to brand Toviaz<sup>®</sup>. The specific PA requirements and tier chart for the Bladder Control Medications can be found on the OHCA website in the “Genitourinary System” therapeutic category.

**Cerdelga<sup>®</sup> and Zavesca<sup>®</sup>**

Cerdelga<sup>®</sup> (eliglustat) will require prior authorization. Members currently utilizing Cerdelga<sup>®</sup> will be approved for continuation of therapy.

Zavesca<sup>®</sup> (miglustat) will be brand preferred. Members currently utilizing generic miglustat will need to switch to brand Zavesca<sup>®</sup>.

The specific PA requirements for the Lysosomal Storage Disease Medications can be found on the OHCA website in the “Genetic Disorders” therapeutic category.

**Alphagan<sup>®</sup> P and Zioptan<sup>®</sup>**

Alphagan<sup>®</sup> P (brimonidine) and Zioptan<sup>®</sup> (tafluprost) will be brand preferred. Members currently utilizing generic brimonidine or tafluprost will need to switch to brand Alphagan<sup>®</sup> P or Zioptan<sup>®</sup> respectfully. The specific PA requirements and tier charts for the Glaucoma Medications can be found on the OHCA website in the “Ocular/Otic” therapeutic category.

**Ciprodex<sup>®</sup> and Floxin<sup>®</sup> Otic**

Ciprodex<sup>®</sup> (ciprofloxacin/dexamethasone) will be moved to tier-2 of the otic anti-infectives tier chart. Floxin<sup>®</sup> Otic (ofloxacin) will be moved to tier-1 of the otic anti-infectives tier chart. The complete tier chart can be found on the OHCA website in the “Ocular/Otic” therapeutic category.

**Reminder:**

Please file a claim with the primary insurance before filing a claim with SoonerCare. If you receive a denied claim due to other insurance coverage and the member states there is not primary pharmacy coverage, please have the member call SoonerCare.

Thank you for the services you provide to Oklahomans insured by SoonerCare!

---

**SOONERCARE PHARMACY SERVICES • PHARMACY MANAGEMENT CONSULTANTS**



**ADDRESS**

4345 N. Lincoln Blvd.  
Oklahoma City, OK 73105



**WEBSITES**

[oklahoma.gov/ohca](http://oklahoma.gov/ohca)  
[mysoonerCare.org](http://mysoonerCare.org)



**PHONE**

Admin: 405-522-7300  
Helpline: 800-987-7767